GNMSF
Price
$332.00
Change
-$0.00 (-0.00%)
Updated
Oct 17 closing price
Capitalization
20.48B
RIGL
Price
$27.94
Change
-$0.17 (-0.60%)
Updated
Oct 17 closing price
Capitalization
501.17M
Interact to see
Advertisement

GNMSF vs RIGL

Header iconGNMSF vs RIGL Comparison
Open Charts GNMSF vs RIGLBanner chart's image
Genmab A/S
Price$332.00
Change-$0.00 (-0.00%)
Volume$5
Capitalization20.48B
Rigel Pharmaceuticals
Price$27.94
Change-$0.17 (-0.60%)
Volume$383.57K
Capitalization501.17M
GNMSF vs RIGL Comparison Chart in %
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNMSF vs. RIGL commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNMSF is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (GNMSF: $332.00 vs. RIGL: $27.94)
Brand notoriety: GNMSF and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNMSF: 1% vs. RIGL: 55%
Market capitalization -- GNMSF: $20.48B vs. RIGL: $501.17M
GNMSF [@Biotechnology] is valued at $20.48B. RIGL’s [@Biotechnology] market capitalization is $501.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNMSF’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • GNMSF’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both GNMSF and RIGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNMSF’s TA Score shows that 3 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • GNMSF’s TA Score: 3 bullish, 5 bearish.
  • RIGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than GNMSF.

Price Growth

GNMSF (@Biotechnology) experienced а +5.40% price change this week, while RIGL (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($20.5B) has a higher market cap than RIGL($501M). GNMSF has higher P/E ratio than RIGL: GNMSF (17.17) vs RIGL (5.15). RIGL YTD gains are higher at: 66.112 vs. GNMSF (60.093). GNMSF has higher annual earnings (EBITDA): 1.48B vs. RIGL (109M). GNMSF has more cash in the bank: 2.9B vs. RIGL (108M). RIGL has less debt than GNMSF: RIGL (61M) vs GNMSF (148M). GNMSF has higher revenues than RIGL: GNMSF (3.26B) vs RIGL (268M).
GNMSFRIGLGNMSF / RIGL
Capitalization20.5B501M4,092%
EBITDA1.48B109M1,354%
Gain YTD60.09366.11291%
P/E Ratio17.175.15334%
Revenue3.26B268M1,217%
Total Cash2.9B108M2,684%
Total Debt148M61M243%
FUNDAMENTALS RATINGS
GNMSF vs RIGL: Fundamental Ratings
GNMSF
RIGL
OUTLOOK RATING
1..100
6351
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8595
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RIGL's Valuation (53) in the Biotechnology industry is in the same range as GNMSF (67) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

RIGL's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as GNMSF (100) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

RIGL's SMR Rating (100) in the Biotechnology industry is in the same range as GNMSF (100) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's Price Growth Rating (85) in the null industry is in the same range as RIGL (95) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

GNMSF's P/E Growth Rating (52) in the null industry is somewhat better than the same rating for RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew somewhat faster than RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNMSFRIGL
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
67%
Bullish Trend 3 days ago
70%
Momentum
ODDS (%)
Bearish Trend 3 days ago
69%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
73%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYAVX75.850.32
+0.42%
Rydex S&P MidCap 400 Pure Value H
DHIYX21.18N/A
N/A
Diamond Hill International Y
FGFCX41.59N/A
N/A
Federated Hermes International Leaders C
WSCRX36.38-0.11
-0.30%
Allspring Small Company Growth R6
ODICX48.20-0.28
-0.58%
Invesco Discovery C

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
N/A
GMAB - GNMSF
58%
Loosely correlated
+1.28%
RIGL - GNMSF
29%
Poorly correlated
-0.60%
ARCT - GNMSF
28%
Poorly correlated
-4.92%
ATNM - GNMSF
27%
Poorly correlated
N/A
AGIO - GNMSF
27%
Poorly correlated
+1.95%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with AGIO. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
-0.60%
AGIO - RIGL
37%
Loosely correlated
+1.95%
RNA - RIGL
37%
Loosely correlated
-1.82%
MIRM - RIGL
37%
Loosely correlated
-1.20%
FTRE - RIGL
36%
Loosely correlated
-0.74%
MNMD - RIGL
35%
Loosely correlated
+14.61%
More